Immunocore Q3 2026: sales dip after Q2 stocking; key melanoma trial data slips to Q2 2027
Did the story change? Mixed
Partly. Kimmtrak sales were $102.2 million, down 1% from a year earlier and 12% from Q2, which Immunocore attributes to wholesaler stocking in Q2 and an extra sales week last year; it puts underlying growth at about 10%. Topline data from TEBE-AM, the trial that could widen Kimmtrak's use, is now expected in Q2 2027, not as early as the end of 2026. Shares closed up 9.1% at $30.99 on Nov 6.
What it means
- What changed
- Immunocore now expects TEBE-AM survival data in Q2 2027, and it plans a new Phase 2/3 trial combining Kimmtrak with brenetafusp.
- What hasn't changed
- Kimmtrak is still the only source of sales, and Immunocore still expects to pay about $120 million of rebate accruals, now in Q4.
- Next · Q2 2027
- Topline overall survival from TEBE-AM in previously treated advanced melanoma; the trial is event-driven.
Closing prices: $30.99 on Nov 6, 2026 (Yahoo Finance, CNBC) and $28.40 on Nov 5 (Nasdaq, Yahoo Finance, CNBC).
Snapshot at the Nov 6, 2026 close
- Market value
- $1.6B
- Enterprise value
- $1.1B
- Price/sales
- 3.7×
- EV/sales
- 2.6×
- P/E
- n/m
- Price/FCF
- n/m
- Revenue growth
- +13%
- FCF margin
- −4%
- Net cash
- $507M
Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 6, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $30.99 (official close, Yahoo Finance, CNBC); 51.7 million shares (common shares on the cover page of the 10-Q filed Nov 6, 2026). n/m = not meaningful (e.g. negative earnings).
Immunocore’s only drug sold less than in Q2 and slightly less than a year earlier, though the company says most of that is timing. The bigger change is in the pipeline: data from the trial that could widen Kimmtrak’s use is now due in Q2 2027.
How the stock reacted
Immunocore closed at $30.99 on Nov 6, up 9.1% from the Nov 5 close of $28.40 (Yahoo Finance, CNBC). The shares had fallen 18% this year to that close, from $34.71 at the end of 2025 (Yahoo Finance, our calculation). No report we found explains the move.
Did the story change?
In September Immunocore expected TEBE-AM topline data “as early as the end of 2026”; it now expects it in Q2 2027. The table compares Q2 with Q3.
| Driver | Q2 → Q3 2026 | Management: before → now | Signal |
|---|---|---|---|
| Kimmtrak net sales | $115.9M → $102.2M (US $74.9M → $62.2M; Europe $34.1M → $34.9M) | “Moderating revenue growth” expected for 2026, no numeric guide → underlying growth “approximately 10%” year on year, on its adjustment for Q2 stocking and an extra week last year | Unchanged |
| TEBE-AM (previously treated advanced melanoma) | Enrollment near target → 540 patients enrolled, reached in September | “As early as the end of 2026” → Q2 2027 | Worse |
| Combination of Kimmtrak and brenetafusp | Phase 1 data pending → data at SITC | No disclosed randomized plan for this combination → planning DUET-UVEAL, a Phase 2/3 trial; no start date | Better |
| Net result | Loss of $0.8M → loss of $14.2M | First-half profit was $12.2M → nine-month loss of $2.1M | Worse |
| Cash and investments | $880.2M → $901.3M | About $120M of rebate payments expected in 2H → now in Q4 | Watch |
Sources: Q2 and Q3 releases and 10-Qs; the Sep 14 release. Comparisons are our calculations from reported figures.
What got better
The combination data gives Immunocore a new path in its home disease. In 17 evaluable first-line patients with metastatic uveal melanoma given Kimmtrak plus brenetafusp, it reported a 29% response rate and a 70% two-year survival rate. These are early results without a control group, in a small group, as Immunocore reports them. It calls them the first data showing activity for two T cell engagers combined in a solid tumor, and it is planning the DUET-UVEAL trial on that basis; it gave no start date.
Cash and investments rose by about $21 million in the quarter, and nine-month sales were up 10%. After quarter-end, Immunocore dosed the first person with type 1 diabetes in its IMC-S118AI trial.
What needs watching
Expansion beyond Kimmtrak’s current use still depends on trials whose results are pending. Analysts at Jefferies argued in March, when they downgraded the stock to Hold, that Kimmtrak was nearing peak sales and that further upside needs at least one of the two melanoma Phase 3 trials to succeed, Investing.com reported. Immunocore says it still has room to grow through US community and global use, and through two possible new uses.
The later TEBE-AM date moves that test back by at least a quarter. Immunocore says the trial is event-driven but does not explain the change. Others are moving in the same patients: Replimune’s newly approved TUDRIQEV reached its first patients in October, and IDEAYA has filed for approval of its own uveal melanoma combination.
Cash will fall in Q4 if Immunocore pays the roughly $120 million of rebate accruals it expects. Its total accrued revenue deductions were $176.6 million at Sep 30. Our comparison of the two 10-Qs found no new legal matter; Immunocore says it is not a party to any material legal proceedings.
Does this change the long-term story?
Our read: the base business looks steady if Immunocore’s adjustment is right; Q4 sales will provide another check. The roughly 10% figure is management’s estimate, and we can’t reproduce it from what it discloses. The long-term case depends on TEBE-AM and PRISM-MEL-301, and the first of those now reads out later than it had hoped.
For the full record of filings, dilution and cash, see Immunocore: The Long View.
What to watch next
- Later in 2026
- Clinical data for brenetafusp in ovarian and lung cancer at a medical conference, and an application to start trials of IMC-U120AI in skin disease.
- Q4 2026
- Immunocore expects to pay about $120 million in sales-related rebate accruals, which would lower cash.
- Early 2027
- Results from higher doses of IMC-M113V, Immunocore's candidate in HIV.
- Q2 2027
- Topline overall survival from the Phase 3 TEBE-AM trial in previously treated advanced melanoma.
Quick questions
Why did Kimmtrak sales fall in Q3?
Immunocore points to US wholesalers stocking up in Q2 and to one extra sales week in Q3 2025. Adjusting for those two items, it puts underlying growth at about 10%. It reported sales of $102.2 million against $103.7 million a year earlier.
Why did the TEBE-AM date move?
Immunocore says the trial is event-driven, meaning results come after enough patient events occur, and now expects topline data in Q2 2027. Its release does not explain the change from its earlier "as early as the end of 2026".
Updates
- : Updated to the Nov 6 close: $30.99, up 9.1%.
About Immunocore: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
+ 7 more
Accessed Nov 6, 2026: Immunocore: TEBE-AM enrollment release (SEC 8-K, Sep 14, 2026) · Immunocore: Q2 2026 results (SEC 8-K, Exhibit 99.1) · Immunocore: Q2 2026 Form 10-Q · Roic AI: Immunocore Q2 2026 call transcript (Aug 6, 2026) · Investing.com: Jefferies downgrades Immunocore (Mar 16, 2026) · IDEAYA: Q3 2026 business update (Nov 3, 2026) · Replimune: fiscal Q2 2027 update (Oct 28, 2026)
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.